Haven’t we all heard it a billion times? ‘There are other priorities’ more urgent than defeating ageing. This article attempts to rebut that objection.
Somebody think of the children!!!
—Every social justice warrior ever
Sigh.
Haven’t we all heard it a billion times? ‘There are other priorities’ more urgent than defeating ageing. This article attempts to rebut that objection.
Somebody think of the children!!!
—Every social justice warrior ever
Sigh.
A short summary of the recent senescent cell removal therapy being developed by a team in the Netherlands.
A quick summary of the new FOXO4 senescent cell removal therapy by Dr. Oliver Medvedik from LEAF.
It’s tricky to bring transhumanism into sharp focus. As with, say, feminism, the meaning of the word varies hugely between individuals who identify with it, and the level of commitment may vary between an occasional affirmation or a crusading passion. Like feminism, transhumanism has many factions, often at war with one another, or with the broader culture; as with feminism, a lot of people identify as transhumanist without spending much time learning what those who coined the term were actually on about. Transhumanism broadly considers technology as an emancipatory route to individual and/or collective transcendence over the ‘limitations’ of the human condition.
This contains information that is not in other articles on the same topic of David Sinclair:
“The results certainly sound encouraging. Before he started taking a 500mg NMN pill every morning, 47-year-old Professor Sinclair had his blood tested and was told his body had a biological age of 58.
After consuming NMN for three months, he was tested again and his biological age was 32.”
Continue reading “New pill considered key in the fight against ageing” »
Billionaire investor Jim Mellon has joined the push to solve age-related diseases and bring rejuvenation biotechnology to the world.
Billionaire biotechnology investor Jim Mellon has unveiled an investment in an ambitious new venture which seeks to tackle ageing and age-related diseases.
Insilico Medicine is a big data analytics company which says its mission is to ‘extend healthy longevity’.
Continue reading “Billionaire Jim Mellon invests in anti-ageing research firm” »
https://www.youtube.com/watch?v=kEGccyXSQAU
New one from Liz.
Full Video ► https://goo.gl/tHvTF5
BioViva ► http://bioviva-science.com
The ruling class tell us universal healthcare is ‘unfeasible’ while they pour millions into immortality drugs and seek godhood itself.
Interest in rejuvenation biotechnology is growing rapidly and attracting investors.
- Jim Mellon has made an investment in Insilico Medicine to enable the company to validate the many molecules discovered using deep learning and launch multi-modal biomarkers of human aging
Monday, April 10, 2017, Baltimore, MD — Insilico Medicine, Inc, a big data analytics company applying deep learning techniques to drug discovery, biomarker development, and aging research today announced that it has closed an investment from the billionaire biotechnology investor Jim Mellon. Proceeds will be used to perform pre-clinical validation of multiple lead molecules developed using Insilico Medicine’s drug discovery pipelines and to advance research in deep learned biomarkers of aging and disease.
Dismantling the idea that older generations should ‘step down’ for younger ones.
Humans are really pros at sugarcoating. If you say old people should step down for the sake of new generations, it sounds so noble and rightful, doesn’t it? What it actually means, though, is ‘We value old people less than new ones,’ and this doesn’t sound very noble or rightful. This is plain and brutal survival of the species.
Continue reading “Old generations should step down in favour of the new ones” »
Everolimus heading for human clinical trials later this year to treat immune system decline.
The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis.
PureTech have recently announced a joint venture with Novartis called resTORbio and are moving to clinical trials of the new drugs later this year. The aim of the first test phase is to see if the new drug can rejuvenate the immune system of aged people a key reason why we lose the ability to resist diseases as we grow older.
Continue reading “New drug aimed at slowing aging heads to the clinic” »